🎉 M&A multiples are live!
Check it out!

Mirum Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Mirum Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Mirum Pharmaceuticals Overview

About Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.


Founded

2018

HQ

United States of America
Employees

322

Website

mirumpharma.com

Financials

LTM Revenue $363M

LTM EBITDA -$54.7M

EV

$2.0B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Mirum Pharmaceuticals Financials

Mirum Pharmaceuticals has a last 12-month revenue of $363M and a last 12-month EBITDA of -$54.7M.

In the most recent fiscal year, Mirum Pharmaceuticals achieved revenue of $337M and an EBITDA of -$49.0M.

Mirum Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Mirum Pharmaceuticals valuation multiples based on analyst estimates

Mirum Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $186M $337M XXX XXX XXX
Gross Profit $64.7M $139M XXX XXX XXX
Gross Margin 35% 41% XXX XXX XXX
EBITDA -$136M -$49.0M XXX XXX XXX
EBITDA Margin -73% -15% XXX XXX XXX
Net Profit -$136M -$163M XXX XXX XXX
Net Margin -73% -49% XXX XXX XXX
Net Debt n/a $20.1M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Mirum Pharmaceuticals Stock Performance

As of April 15, 2025, Mirum Pharmaceuticals's stock price is $40.

Mirum Pharmaceuticals has current market cap of $1.9B, and EV of $2.0B.

See Mirum Pharmaceuticals trading valuation data

Mirum Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.0B $1.9B XXX XXX XXX XXX $-1.59

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Mirum Pharmaceuticals Valuation Multiples

As of April 15, 2025, Mirum Pharmaceuticals has market cap of $1.9B and EV of $2.0B.

Mirum Pharmaceuticals's trades at 5.4x LTM EV/Revenue multiple, and -36.2x LTM EBITDA.

Analysts estimate Mirum Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Mirum Pharmaceuticals and 10K+ public comps

Mirum Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.0B XXX XXX XXX
EV/Revenue 5.9x XXX XXX XXX
EV/EBITDA -40.4x XXX XXX XXX
P/E -22.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -185.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Mirum Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Mirum Pharmaceuticals Valuation Multiples

Mirum Pharmaceuticals's NTM/LTM revenue growth is 25%

Mirum Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Mirum Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Mirum Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Mirum Pharmaceuticals and other 10K+ public comps

Mirum Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 81% XXX XXX XXX XXX
EBITDA Margin -15% XXX XXX XXX XXX
EBITDA Growth -64% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 10% XXX XXX XXX XXX
Revenue per Employee $1.0M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 42% XXX XXX XXX XXX
Opex to Revenue 102% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Mirum Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Mirum Pharmaceuticals M&A and Investment Activity

Mirum Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Mirum Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Mirum Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Mirum Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Mirum Pharmaceuticals

When was Mirum Pharmaceuticals founded? Mirum Pharmaceuticals was founded in 2018.
Where is Mirum Pharmaceuticals headquartered? Mirum Pharmaceuticals is headquartered in United States of America.
How many employees does Mirum Pharmaceuticals have? As of today, Mirum Pharmaceuticals has 322 employees.
Who is the CEO of Mirum Pharmaceuticals? Mirum Pharmaceuticals's CEO is Mr. Christopher Peetz.
Is Mirum Pharmaceuticals publicy listed? Yes, Mirum Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Mirum Pharmaceuticals? Mirum Pharmaceuticals trades under MIRM ticker.
When did Mirum Pharmaceuticals go public? Mirum Pharmaceuticals went public in 2019.
Who are competitors of Mirum Pharmaceuticals? Similar companies to Mirum Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Mirum Pharmaceuticals? Mirum Pharmaceuticals's current market cap is $1.9B
What is the current revenue of Mirum Pharmaceuticals? Mirum Pharmaceuticals's last 12-month revenue is $363M.
What is the current EBITDA of Mirum Pharmaceuticals? Mirum Pharmaceuticals's last 12-month EBITDA is -$54.7M.
What is the current EV/Revenue multiple of Mirum Pharmaceuticals? Current revenue multiple of Mirum Pharmaceuticals is 5.4x.
What is the current EV/EBITDA multiple of Mirum Pharmaceuticals? Current EBITDA multiple of Mirum Pharmaceuticals is -36.2x.
What is the current revenue growth of Mirum Pharmaceuticals? Mirum Pharmaceuticals revenue growth between 2023 and 2024 was 81%.
Is Mirum Pharmaceuticals profitable? Yes, Mirum Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.